Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.22)
# 2,783
Out of 5,146 analysts
112
Total ratings
40.4%
Success rate
-2.02%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Maintains: Buy | $15 → $20 | $7.33 | +172.85% | 5 | Feb 18, 2026 | |
| BIIB Biogen | Maintains: Buy | $220 → $230 | $188.02 | +22.33% | 22 | Feb 9, 2026 | |
| GHRS GH Research | Maintains: Buy | $35 → $39 | $15.63 | +149.52% | 5 | Jan 6, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $28 → $36 | $35.55 | +1.27% | 5 | Jan 5, 2026 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $25 → $24 | $9.09 | +164.03% | 7 | Nov 6, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $160 → $164 | $130.64 | +25.54% | 17 | Oct 29, 2025 | |
| ATAI AtaiBeckley | Maintains: Buy | $11 → $14 | $3.73 | +275.34% | 4 | Oct 22, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $17 | $2.77 | +513.72% | 4 | Sep 30, 2025 | |
| CLNN Clene | Maintains: Buy | $83 → $48 | $5.36 | +795.52% | 6 | Aug 18, 2025 | |
| CRVO CervoMed | Maintains: Buy | $21 → $27 | $4.40 | +513.64% | 6 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $4.23 | +183.69% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $1.76 | +4,445.45% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $24.64 | +33.93% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $11.15 | +1,245.29% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $33.77 | - | 2 | Jan 31, 2017 |
COMPASS Pathways
Feb 18, 2026
Maintains: Buy
Price Target: $15 → $20
Current: $7.33
Upside: +172.85%
Biogen
Feb 9, 2026
Maintains: Buy
Price Target: $220 → $230
Current: $188.02
Upside: +22.33%
GH Research
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $39
Current: $15.63
Upside: +149.52%
Stoke Therapeutics
Jan 5, 2026
Maintains: Buy
Price Target: $28 → $36
Current: $35.55
Upside: +1.27%
Zevra Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $25 → $24
Current: $9.09
Upside: +164.03%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Buy
Price Target: $160 → $164
Current: $130.64
Upside: +25.54%
AtaiBeckley
Oct 22, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $3.73
Upside: +275.34%
Annovis Bio
Sep 30, 2025
Maintains: Buy
Price Target: $17
Current: $2.77
Upside: +513.72%
Clene
Aug 18, 2025
Maintains: Buy
Price Target: $83 → $48
Current: $5.36
Upside: +795.52%
CervoMed
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $4.40
Upside: +513.64%
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $4.23
Upside: +183.69%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.76
Upside: +4,445.45%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $24.64
Upside: +33.93%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $11.15
Upside: +1,245.29%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $33.77
Upside: -